ClinicalTrials.gg

Program

Herpes Zoster Vaccine

Also written as “Herpes Zoster Vaccine, Live”, “Herpes Zoster vaccine (GSK 1437173A)” and “Herpes Zoster vaccine (GSK1437173A)”.

Its studies are mostly in Herpes Zoster, led by 2 companies.

Furthest: phase 4, since Jan 10, 20134 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline30 open or runningphase 3since Jan 10, 2013Jan 10, 2013none ahead
Changchun BCHT Biotechnology11 open or runningphase 4since Apr 23, 2025Apr 23, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 10, 2013First study: phase 3 study in Herpes ZosterNew to GlaxoSmithKlineGlaxoSmithKline · NCT01767467 · 568 enrolled · United States, Australia, Belgium and more
  2. Mar 28, 2013Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT01827839 · 96 enrolled · Canada, Russian Federation
  3. Feb 27, 2014Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02075515 · 651 enrolled · United States, Belgium, Canada
  4. Apr 23, 2025Changchun BCHT Biotechnology’s first study: phase 4 study in Herpes ZosterNew to Changchun BCHT BiotechnologyChangchun BCHT Biotechnology · NCT06961721 · 600 planned

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06961721Herpes Zoster4Not yet recruitingChangchun BCHT BiotechnologyJul 2025600
NCT02075515Herpes Zoster · United States, Belgium, Canada3CompletedGlaxoSmithKlineApr 29, 2015651
NCT01827839Herpes Zoster · Canada, Russian Federation3CompletedGlaxoSmithKlineFeb 10, 201496
NCT01767467Herpes Zoster · United States, Australia, Belgium and more3CompletedGlaxoSmithKlineJan 7, 2016568

How it is read

Names in the registry

  • “Herpes Zoster Vaccine, Live”, 1 entry
  • “Herpes Zoster vaccine (GSK 1437173A)”, 1 entry
  • “Herpes Zoster vaccine (GSK1437173A)”, 1 entry
  • “Herpes zoster vaccine (GSK 1437173A)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.